Drug Trial Radar · NCT06886269
A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose
Last checked: Nov 19, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Mar 21, 2025
Primary completion
May 17, 2025
Study completion May 17, 2025
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Mar 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the routes and rate of elimination and recovery of total radioactivity (TRA) and characterize the Pharmacokinetic (PK) of VX-993 after a single oral dose of 14C-VX-993.
Conditions
- Pain
Interventions
14C-VX-993Drug
Solution for Oral Administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Terminal Phase Rate Constant (λz) of VX-993 in PlasmaTime frame: From Day 1 up to Day 25
- Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-tlast) of VX-993 in PlasmaTime frame: From Day 1 up to Day 25
- Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-993 in PlasmaTime frame: From Day 1 up to Day 25
- Apparent Clearance (CL/F) of VX-993 in PlasmaTime frame: From Day 1 up to Day 25
- Maximum Observed Plasma Concentration (Cmax) of VX-993 in PlasmaTime frame: From Day 1 up to Day 25
- Time for VX-993 to Reach Maximum Concentration (Tmax) in PlasmaTime frame: From Day 1 up to Day 25
- Apparent Volume of Distribution (Vz/F) (Based on the Terminal Phase) of VX-993 in PlasmaTime frame: From Day 1 up to Day 25
- Terminal Phase Rate Constant (λz) of Total Radioactivity (TRA) in Whole blood and PlasmaTime frame: From Day 1 up to Day 25
- Amount of Radioactivity Excreted (Ae) of TRA in Urine, Feces and Vomitus (if applicable)Time frame: Pre dose up to Day 25
- AUC0-tlast of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 25
- AUC0-inf of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 25
- CL/F of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 25
- Renal Clearance (CLr) of TRA in Urine and FecesTime frame: Pre dose up to Day 25
- Cmax of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 25
- Fraction (percent) of Dose Excreted Unchanged in Urine of TRATime frame: Pre dose up to Day 25
- Tmax of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 25
- Apparent Volume of Distribution (Based on the Terminal Phase) of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 25
- Amount of VX-993 and Metabolites, Expressed as a percent of TRA, in Plasma, Urine and FecesTime frame: From Day 1 up to Day 25
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion - Lincoln
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.